NR 566 ADVANCED PHARMACOLOGY MIDTERM EXAM
2026/2027 | Care of the Family | Rated A | Complete
Questions & Verified Answers | Chamberlain | Pass
Guaranteed - A+ Graded
Section 1: Foundational Pharmacology Principles
10 questions covering pharmacokinetics, pharmacodynamics, drug interactions, and
adverse reactions
Q1: A 72-year-old patient with heart failure is prescribed a new medication that is highly
protein-bound (95%). They have low albumin levels due to malnutrition. Which
pharmacokinetic change is most likely to occur?
A. Decreased drug metabolism leading to toxicity
B. Increased free drug concentration and potential toxicity
C. Enhanced renal excretion of the drug
D. Reduced absorption from the gastrointestinal tract
Correct Answer: B
Rationale: When albumin is low, less drug binds to protein, leaving more free (active)
drug circulating. That's why we see toxicity in malnourished elderly patients even with
"normal" total drug levels. The best choice here is increased free concentration.
,Q2: A patient is taking warfarin and starts taking ciprofloxacin for a urinary tract
infection. Which type of drug interaction is occurring, and what is the expected result?
A. Pharmacodynamic interaction resulting in reduced anticoagulation
B. Pharmacokinetic interaction through CYP3A4 inhibition, increasing INR
C. Pharmacokinetic interaction through CYP1A2 inhibition, increasing INR
D. Pharmacodynamic interaction resulting in increased bleeding risk only
Correct Answer: C
Rationale: Ciprofloxacin inhibits CYP1A2, which metabolizes warfarin's R-enantiomer.
That bumps up the INR, sometimes dramatically. I always warn students to check INR
within 3-5 days when starting any fluoroquinolone with warfarin.
Q3: A 45-year-old with hypertension is prescribed a prodrug that requires activation by
liver enzymes. They have cirrhosis with Child-Pugh Class B severity. Which adjustment
is most appropriate?
A. Increase the dose to overcome reduced activation
B. Avoid the prodrug and select an active alternative
C. Reduce the dose by 25% and monitor closely
D. No adjustment needed; administer as prescribed
Correct Answer: B
Rationale: Prodrugs like codeine or enalapril need functional liver enzymes to become
active. In Child-Pugh B, that conversion is unpredictable—sometimes insufficient,
,sometimes generating toxic metabolites. Better to pick something that doesn't need
liver activation.
Q4: A patient on chronic morphine therapy for cancer pain develops tolerance requiring
dose escalation. Which statement best describes this phenomenon?
A. Tolerance indicates addiction and requires immediate discontinuation
B. Tolerance is a pharmacodynamic adaptation requiring dose adjustment
C. Tolerance results from increased drug metabolism only
D. Tolerance means the underlying pain condition has worsened
Correct Answer: B
Rationale: Tolerance is expected with chronic opioids—receptors downregulate and
signaling adapts. In palliative care, we expect to increase doses over time. That's
completely different from addiction, which is compulsive use despite harm.
Q5: A drug has a half-life of 8 hours. Approximately how long will it take to reach
steady-state concentration with daily dosing?
A. 8 hours
B. 24 hours
C. 40 hours (approximately 5 half-lives)
D. 80 hours (approximately 10 half-lives)
Correct Answer: C
, Rationale: Remember the 5 half-lives rule for steady state—whether you're starting
therapy or waiting for washout. With an 8-hour half-life, you're looking at about 40 hours
to reach steady plasma levels. That's why we don't judge antidepressant efficacy for at
least 4-6 weeks.
Q6: A patient taking digoxin develops toxicity with nausea, visual disturbances, and
ventricular arrhythmias. Their potassium level is 2.8 mEq/L. Which statement explains
this interaction?
A. Hypokalemia displaces digoxin from tissue binding sites, increasing free drug
B. Hypokalemia reduces digoxin absorption from the GI tract
C. Hypokalemia enhances digoxin metabolism in the liver
D. Hypokalemia has no effect on digoxin pharmacology
Correct Answer: A
Rationale: Digoxin and potassium compete for the same binding site on the
Na-K-ATPase pump. When potassium is low, digoxin binds more avidly, effectively
increasing its concentration at the receptor. That's why we check electrolytes before
starting digoxin and hold diuretics if needed.
Q7: A patient is prescribed a medication that is a substrate of P-glycoprotein. They start
taking St. John's Wort, a known P-gp inducer. What is the expected clinical effect?
A. Increased drug absorption and potential toxicity
B. Decreased drug bioavailability and therapeutic failure
C. No significant interaction expected
2026/2027 | Care of the Family | Rated A | Complete
Questions & Verified Answers | Chamberlain | Pass
Guaranteed - A+ Graded
Section 1: Foundational Pharmacology Principles
10 questions covering pharmacokinetics, pharmacodynamics, drug interactions, and
adverse reactions
Q1: A 72-year-old patient with heart failure is prescribed a new medication that is highly
protein-bound (95%). They have low albumin levels due to malnutrition. Which
pharmacokinetic change is most likely to occur?
A. Decreased drug metabolism leading to toxicity
B. Increased free drug concentration and potential toxicity
C. Enhanced renal excretion of the drug
D. Reduced absorption from the gastrointestinal tract
Correct Answer: B
Rationale: When albumin is low, less drug binds to protein, leaving more free (active)
drug circulating. That's why we see toxicity in malnourished elderly patients even with
"normal" total drug levels. The best choice here is increased free concentration.
,Q2: A patient is taking warfarin and starts taking ciprofloxacin for a urinary tract
infection. Which type of drug interaction is occurring, and what is the expected result?
A. Pharmacodynamic interaction resulting in reduced anticoagulation
B. Pharmacokinetic interaction through CYP3A4 inhibition, increasing INR
C. Pharmacokinetic interaction through CYP1A2 inhibition, increasing INR
D. Pharmacodynamic interaction resulting in increased bleeding risk only
Correct Answer: C
Rationale: Ciprofloxacin inhibits CYP1A2, which metabolizes warfarin's R-enantiomer.
That bumps up the INR, sometimes dramatically. I always warn students to check INR
within 3-5 days when starting any fluoroquinolone with warfarin.
Q3: A 45-year-old with hypertension is prescribed a prodrug that requires activation by
liver enzymes. They have cirrhosis with Child-Pugh Class B severity. Which adjustment
is most appropriate?
A. Increase the dose to overcome reduced activation
B. Avoid the prodrug and select an active alternative
C. Reduce the dose by 25% and monitor closely
D. No adjustment needed; administer as prescribed
Correct Answer: B
Rationale: Prodrugs like codeine or enalapril need functional liver enzymes to become
active. In Child-Pugh B, that conversion is unpredictable—sometimes insufficient,
,sometimes generating toxic metabolites. Better to pick something that doesn't need
liver activation.
Q4: A patient on chronic morphine therapy for cancer pain develops tolerance requiring
dose escalation. Which statement best describes this phenomenon?
A. Tolerance indicates addiction and requires immediate discontinuation
B. Tolerance is a pharmacodynamic adaptation requiring dose adjustment
C. Tolerance results from increased drug metabolism only
D. Tolerance means the underlying pain condition has worsened
Correct Answer: B
Rationale: Tolerance is expected with chronic opioids—receptors downregulate and
signaling adapts. In palliative care, we expect to increase doses over time. That's
completely different from addiction, which is compulsive use despite harm.
Q5: A drug has a half-life of 8 hours. Approximately how long will it take to reach
steady-state concentration with daily dosing?
A. 8 hours
B. 24 hours
C. 40 hours (approximately 5 half-lives)
D. 80 hours (approximately 10 half-lives)
Correct Answer: C
, Rationale: Remember the 5 half-lives rule for steady state—whether you're starting
therapy or waiting for washout. With an 8-hour half-life, you're looking at about 40 hours
to reach steady plasma levels. That's why we don't judge antidepressant efficacy for at
least 4-6 weeks.
Q6: A patient taking digoxin develops toxicity with nausea, visual disturbances, and
ventricular arrhythmias. Their potassium level is 2.8 mEq/L. Which statement explains
this interaction?
A. Hypokalemia displaces digoxin from tissue binding sites, increasing free drug
B. Hypokalemia reduces digoxin absorption from the GI tract
C. Hypokalemia enhances digoxin metabolism in the liver
D. Hypokalemia has no effect on digoxin pharmacology
Correct Answer: A
Rationale: Digoxin and potassium compete for the same binding site on the
Na-K-ATPase pump. When potassium is low, digoxin binds more avidly, effectively
increasing its concentration at the receptor. That's why we check electrolytes before
starting digoxin and hold diuretics if needed.
Q7: A patient is prescribed a medication that is a substrate of P-glycoprotein. They start
taking St. John's Wort, a known P-gp inducer. What is the expected clinical effect?
A. Increased drug absorption and potential toxicity
B. Decreased drug bioavailability and therapeutic failure
C. No significant interaction expected
